Abstract
Background: Our research focuses on local level estimation of the effective reproductive number, which describes the transmissibility of an infectious disease and represents the average number of individuals one infectious person infects at a given time. The ability to accurately estimate the infectious disease reproductive number in geographically granular regions is critical for disaster planning and resource allocation. However, not all regions have sufficient infectious disease outcome data for estimation. Methods: To overcome this challenge, we propose a two-step approach that incorporates existing Rt estimation procedures (EpiEstim, EpiFilter, EpiNow2) using data from geographic regions with sufficient data (step 1) into a covariate-adjusted Bayesian Integrated Nested Laplace Approximation (INLA) spatial model to predict Rt in regions with sparse or missing data (step 2). Our flexible framework effectively allows us to implement any existing estimation procedure for Rt in regions with coarse or entirely missing data. We perform external validation and a simulation study to evaluate the proposed method and assess its predictive performance. Results: We applied our method to estimate Rt using data from South Carolina (SC) counties and ZIP codes during the first COVID-19 wave (Wave 1, June 16, 2020 to August 31, 2020) and the second wave (Wave 2, December 16, 2020 to March 02, 2021). Among the three methods used in the first step, EpiNow2 yielded the highest accuracy of Rt prediction in the regions with entirely missing data. Median county-level percentage agreement (PA) was 90.9% (Interquartile Range, IQR: 89.9-92.0%) and 92.5% (IQR: 91.6 to 93.4%) for Wave 1 and 2, respectively. Median zip code level PA was 95.2% (IQR: 94.4 to 95.7%) and 96.5% (IQR: 95.8 to 97.1%) for Wave 1 and 2, respectively. Using EpiEstim, EpiFilter, and an ensemble-based approach yielded median PA ranging from 81.9% to 90.0%, 87.2% to 92.1%, and 88.4% to 90.9%, respectively, across both waves and geographic granularities. Conclusion: These findings demonstrate that the proposed methodology is a useful tool for small-area estimation of Rt, as our flexible framework yields high prediction accuracy for regions with coarse or missing data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MSH, RG, NKM, and VDG acknowledge support from the National Library of Medicine of the National Institutes of Health (NIH) under award number R01LM014193. LR and CM acknowledge support from the National Library of Medicine of the National Institutes of Health (NIH) under award number R01LM014193 and the Center for Forecasting and Outbreak Analytics of the Centers for Disease Control and Prevention (CDC) under award number NU38FT000011. MMC recognizes support from the Center for Forecasting and Outbreak Analytics of the Centers for Disease Control and Prevention (CDC) under award number NU38FT000011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical review for this study was obtained by the Institutional Review Board of Clemson University (#2020-0150). No consent was needed for this study; retrospective data is based on medical claims and electronic health records and were de-identified to study investigators.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos